Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker
A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 d
